α-tocopherol supplementation decreases plasminogen activator inhibitor-1 and P-selectin levels in type 2 diabetic patients

Sridevi Devaraj, Alberto V. Cabo Chan, Ishwarlal Jialal

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

OBJECTIVE - Type 2 diabetic subjects have an increased propensity to premature atherothrombosis. α-Tocopherol (AT), a potent antioxidant, has anti-inflammatory properties at high doses. The aim of the study was to test the effect of natural (RRR)-AT supplementation (1,200 IU/day) on markers of thrombosis, plasminogen activator inhibitor-1 (PAI-1), and soluble P-selectin (sP-selectin) in type 2 diabetic patients with and without macrovascular complications (MVCs) compared with matched control subjects. RESEARCH DESIGN AND METHODS - The volunteers comprised type 2 diabetic patients with (n = 23) and without (n = 24) MVCs and matched control subjects (n = 25). Plasma levels of PAI-1 and P-selectin were assayed at baseline, after 3 months of supplementation, and after a 2-month washout phase. RESULTS - Both diabetic groups had significantly increased levels of PAI-1 compared with control subjects (P < 0.025), whereas only type 2 diabetic patients with MVCs had significantly elevated levels of sP-selectin compared with control subjects. AT supplementation significantly lowered levels of PAI-1 and sP-selectin in all three groups. The reduction in PAI-1 levels with AT supplementation was significantly greater in type 2 diabetic patients with MVCs than in those without MVCs (P = 0.005). CONCLUSIONS - Thus, AT therapy decreases markers of thrombosis in diabetic patients and control subjects and could be an adjunctive therapy in the prevention of atherosclerosis.

Original languageEnglish (US)
Pages (from-to)524-529
Number of pages6
JournalDiabetes Care
Volume25
Issue number3
DOIs
StatePublished - Mar 2002
Externally publishedYes

Fingerprint

P-Selectin
Tocopherols
Plasminogen Activator Inhibitor 1
Thrombosis
Volunteers
Atherosclerosis
Anti-Inflammatory Agents
Research Design
Antioxidants
Therapeutics

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

α-tocopherol supplementation decreases plasminogen activator inhibitor-1 and P-selectin levels in type 2 diabetic patients. / Devaraj, Sridevi; Cabo Chan, Alberto V.; Jialal, Ishwarlal.

In: Diabetes Care, Vol. 25, No. 3, 03.2002, p. 524-529.

Research output: Contribution to journalArticle

Devaraj, Sridevi ; Cabo Chan, Alberto V. ; Jialal, Ishwarlal. / α-tocopherol supplementation decreases plasminogen activator inhibitor-1 and P-selectin levels in type 2 diabetic patients. In: Diabetes Care. 2002 ; Vol. 25, No. 3. pp. 524-529.
@article{916317c584664c8584ec1458435361cf,
title = "α-tocopherol supplementation decreases plasminogen activator inhibitor-1 and P-selectin levels in type 2 diabetic patients",
abstract = "OBJECTIVE - Type 2 diabetic subjects have an increased propensity to premature atherothrombosis. α-Tocopherol (AT), a potent antioxidant, has anti-inflammatory properties at high doses. The aim of the study was to test the effect of natural (RRR)-AT supplementation (1,200 IU/day) on markers of thrombosis, plasminogen activator inhibitor-1 (PAI-1), and soluble P-selectin (sP-selectin) in type 2 diabetic patients with and without macrovascular complications (MVCs) compared with matched control subjects. RESEARCH DESIGN AND METHODS - The volunteers comprised type 2 diabetic patients with (n = 23) and without (n = 24) MVCs and matched control subjects (n = 25). Plasma levels of PAI-1 and P-selectin were assayed at baseline, after 3 months of supplementation, and after a 2-month washout phase. RESULTS - Both diabetic groups had significantly increased levels of PAI-1 compared with control subjects (P < 0.025), whereas only type 2 diabetic patients with MVCs had significantly elevated levels of sP-selectin compared with control subjects. AT supplementation significantly lowered levels of PAI-1 and sP-selectin in all three groups. The reduction in PAI-1 levels with AT supplementation was significantly greater in type 2 diabetic patients with MVCs than in those without MVCs (P = 0.005). CONCLUSIONS - Thus, AT therapy decreases markers of thrombosis in diabetic patients and control subjects and could be an adjunctive therapy in the prevention of atherosclerosis.",
author = "Sridevi Devaraj and {Cabo Chan}, {Alberto V.} and Ishwarlal Jialal",
year = "2002",
month = "3",
doi = "10.2337/diacare.25.3.524",
language = "English (US)",
volume = "25",
pages = "524--529",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "3",

}

TY - JOUR

T1 - α-tocopherol supplementation decreases plasminogen activator inhibitor-1 and P-selectin levels in type 2 diabetic patients

AU - Devaraj, Sridevi

AU - Cabo Chan, Alberto V.

AU - Jialal, Ishwarlal

PY - 2002/3

Y1 - 2002/3

N2 - OBJECTIVE - Type 2 diabetic subjects have an increased propensity to premature atherothrombosis. α-Tocopherol (AT), a potent antioxidant, has anti-inflammatory properties at high doses. The aim of the study was to test the effect of natural (RRR)-AT supplementation (1,200 IU/day) on markers of thrombosis, plasminogen activator inhibitor-1 (PAI-1), and soluble P-selectin (sP-selectin) in type 2 diabetic patients with and without macrovascular complications (MVCs) compared with matched control subjects. RESEARCH DESIGN AND METHODS - The volunteers comprised type 2 diabetic patients with (n = 23) and without (n = 24) MVCs and matched control subjects (n = 25). Plasma levels of PAI-1 and P-selectin were assayed at baseline, after 3 months of supplementation, and after a 2-month washout phase. RESULTS - Both diabetic groups had significantly increased levels of PAI-1 compared with control subjects (P < 0.025), whereas only type 2 diabetic patients with MVCs had significantly elevated levels of sP-selectin compared with control subjects. AT supplementation significantly lowered levels of PAI-1 and sP-selectin in all three groups. The reduction in PAI-1 levels with AT supplementation was significantly greater in type 2 diabetic patients with MVCs than in those without MVCs (P = 0.005). CONCLUSIONS - Thus, AT therapy decreases markers of thrombosis in diabetic patients and control subjects and could be an adjunctive therapy in the prevention of atherosclerosis.

AB - OBJECTIVE - Type 2 diabetic subjects have an increased propensity to premature atherothrombosis. α-Tocopherol (AT), a potent antioxidant, has anti-inflammatory properties at high doses. The aim of the study was to test the effect of natural (RRR)-AT supplementation (1,200 IU/day) on markers of thrombosis, plasminogen activator inhibitor-1 (PAI-1), and soluble P-selectin (sP-selectin) in type 2 diabetic patients with and without macrovascular complications (MVCs) compared with matched control subjects. RESEARCH DESIGN AND METHODS - The volunteers comprised type 2 diabetic patients with (n = 23) and without (n = 24) MVCs and matched control subjects (n = 25). Plasma levels of PAI-1 and P-selectin were assayed at baseline, after 3 months of supplementation, and after a 2-month washout phase. RESULTS - Both diabetic groups had significantly increased levels of PAI-1 compared with control subjects (P < 0.025), whereas only type 2 diabetic patients with MVCs had significantly elevated levels of sP-selectin compared with control subjects. AT supplementation significantly lowered levels of PAI-1 and sP-selectin in all three groups. The reduction in PAI-1 levels with AT supplementation was significantly greater in type 2 diabetic patients with MVCs than in those without MVCs (P = 0.005). CONCLUSIONS - Thus, AT therapy decreases markers of thrombosis in diabetic patients and control subjects and could be an adjunctive therapy in the prevention of atherosclerosis.

UR - http://www.scopus.com/inward/record.url?scp=0036511470&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036511470&partnerID=8YFLogxK

U2 - 10.2337/diacare.25.3.524

DO - 10.2337/diacare.25.3.524

M3 - Article

C2 - 11874941

AN - SCOPUS:0036511470

VL - 25

SP - 524

EP - 529

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 3

ER -